Stock ITCI INTRA-CELLULAR THERAPIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Intra-Cellular Therapies, Inc.

Equities

ITCI

US46116X1019

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-04-15 pm EDT 		5-day change 1st Jan Change
64.76 USD -1.70% Intraday chart for Intra-Cellular Therapies, Inc. -4.34% -9.58%
Mar. 19 Intra-Cellular Therapies CFO Hineline Retiring, Promotes Halstead to President MT
Mar. 19 Intra-Cellular Therapies, Inc. Announces Executive Changes CI

Business Summary

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.

Number of employees: 610

Sales per Business

USD in Million2022Weight2023Weight Delta
Small Molecule Drugs
100.0 %
250 100.0 % 464 100.0 % +85.51%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
250 100.0 % 464 100.0 % +85.51%

Managers

Managers TitleAgeSince
Sharon Mates CEO
 Chief Executive Officer 71 13-08-28
Lawrence Hineline DFI
 Director of Finance/CFO 67 13-08-28
Michael Halstead PSD
 President 51 14-06-30
Willie Earley CTO
 Chief Tech/Sci/R&D Officer - 22-03-31
Suresh Durgam CTO
 Chief Tech/Sci/R&D Officer - -
Karen Sheehy CMP
 Compliance Officer 62 19-07-01
Robert Davis CTO
 Chief Tech/Sci/R&D Officer 73 15-10-31
Juan F. Sanchez IRC
 Investor Relations Contact - 14-03-09
John A. Bardi LAW
 General Counsel - 19-03-25
Michael Olchaskey LAW
 General Counsel - 18-08-31

Members of the board

Members of the board TitleAgeSince
Rory Riggs BRD
 Director/Board Member 71 14-01-07
Joel Marcus BRD
 Director/Board Member 76 13-08-28
Robert van Nostrand BRD
 Director/Board Member 67 14-01-07
Sharon Mates CEO
 Chief Executive Officer 71 13-08-28
Rene Salas BRD
 Director/Board Member 62 22-04-19

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 96,807,191 94,268,187 ( 97.38 %) 0 97.38 %

Shareholders

NameEquities%Valuation
Fidelity Management & Research Co. LLC
11.84 %
11,457,694 11.84 % 793 M $
Vanguard Fiduciary Trust Co.
9.394 %
9,094,302 9.394 % 629 M $
BlackRock Advisors LLC
7.827 %
7,577,317 7.827 % 524 M $
Wasatch Advisors, Inc.
3.747 %
3,627,308 3.747 % 251 M $
Bellevue Asset Management AG
3.168 %
3,066,400 3.168 % 212 M $
Avoro Capital Advisor LLC
2.330 %
2,255,555 2.330 % 156 M $
STATE STREET CORPORATION
2.294 %
2,220,850 2.294 % 154 M $
JPMorgan Investment Management, Inc.
2.127 %
2,059,128 2.127 % 142 M $
BNY Mellon Investment Adviser, Inc.
2.111 %
2,043,528 2.111 % 141 M $
Geode Capital Management LLC
2.068 %
2,001,791 2.068 % 139 M $

Company contact information

Intra-Cellular Therapies, Inc.

430 East 29th Street Suite 900

10016, New York

+646 440 9333

http://www.intracellulartherapies.com
address Intra-Cellular Therapies, Inc.(ITCI)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Ratings for Intra-Cellular Therapies, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
65.88 USD
Average target price
83.05 USD
Spread / Average Target
+26.06%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
INTRA-CELLULAR THERAPIES, INC. Stock Intra-Cellular Therapies, Inc.
-9.56% 6.38B
CSL LIMITED Stock CSL Limited
-2.83% 88.12B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+4.34% 40.6B
BIOGEN INC. Stock Biogen Inc.
-23.95% 28.81B
UCB Stock UCB
+51.39% 24.35B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-5.08% 17.5B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-32.11% 13.54B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-5.10% 13.52B
INCYTE CORPORATION Stock Incyte Corporation
-14.91% 12.09B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
-4.79% 7.88B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. ITCI Stock
  4. Company Intra-Cellular Therapies, Inc.